Saturday, May 2, 2015
- 5:30pm-7:30pm
-
Outcomes of Eculizumab (ANTI-C5) Therapy for Treatment of Refractory Antiobdy-Mediated Rejection (ABMR) and Thrombotic Microangiopathy (TMA)
Poster Session A: Kidney Antibody Mediated Rejection • Exhibit Hall E
- 5:30pm-7:30pm
-
Outcomes of Hepatitis C Virus (HCV) Treatment Following Liver Transplantation in the Era of Direct-Acting Antiviral Medications
Poster Session A: Liver Transplantation: Viral Hepatitis • Exhibit Hall E
- 5:30pm-7:30pm
-
Outcomes of Solid Organ Transplantation in a National Private Health Plan: Comparison to SRTR Reports
- 5:30pm-7:30pm
-
Outcomes of Treatment of Late Antibody-Mediated Rejection in Primary Renal Transplant Recipients – A Single Center Experience
Poster Session A: Kidney Antibody Mediated Rejection • Exhibit Hall E
- 5:30pm-7:30pm
-
Patients Referred to an OPO: Analysis of Potential for Additional DCD Donors
Poster Session A: Donor Management: All Organs • Exhibit Hall E
- 5:30pm-7:30pm
-
Pediatric Living Donor Liver Transplantation at KFSH&RC Implementation of the Laparoscopic Retrieval in a High Volume Center
Poster Session A: Donor Management: All Organs • Exhibit Hall E
- 5:30pm-7:30pm
-
Perioperative Bacterial Colonization and Postoperative Urinary Tract Infection in Kidney Transplant Recipients
Poster Session A: Infection • Exhibit Hall E
- 5:30pm-7:30pm
-
Pertubations in the Urinary Exosome in Transplant Rejection
Poster Session A: Acute Allograft Rejection • Exhibit Hall E
- 5:30pm-7:30pm
-
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
Poster Session A: Liver: Immunosuppression and Rejection • Exhibit Hall E
- 5:30pm-7:30pm
-
PI3Kα and STAT1 Interplay Regulates Human Mesenchymal Stem Cell Immune Polarization
Poster Session A: Preclinical Immunosuppression and Tolerance • Exhibit Hall E
- «Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 30
- Next Page»